Rialto Wealth Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Rialto Wealth Management's BEAM Position: Q3 2026 in Review
Rialto Wealth Management increased its Beam Therapeutics (BEAM) stake by 29% in Q3 2026, buying an estimated $56 and bringing the position to 9 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #1877.
Rialto Wealth Management first reported a position in BEAM in Q2 2025 and has held it in 6 quarters since. The position peaked at $241 in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Rialto Wealth Management held 9 shares of Beam Therapeutics worth $221 as of Q3 2026.
- Rialto Wealth Management bought 2 Beam Therapeutics shares in Q3 2026, an estimated $56.
- Beam Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q3 2026, its #1877 holding.
- Rialto Wealth Management first reported a position in Beam Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Rialto Wealth Management's Beam Therapeutics position peaked at $241 in Q2 2026.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Rialto Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.